Lung Cancers News
Researchers have characterized treatment-related adverse events associated with antibody-drug conjugates in clinical trials.
The number of new lung cancer cases decreased 11% over the last 5 years.
A prospective study compared aprepitant with desloratadine for the relief of treatment-induced pruritus in patients with lung cancer treated with EGFR-TKIs.
While the rate of late-stage NSCLC diagnosis is improving, more needs to be done to increase survival rates. Are there outside factors that affect the stage at diagnosis, and what can we learn from them?
Patients with Medicare Advantage insurance plans have an increased risk of death after certain cancer surgeries, a study suggests.
Adding tremelimumab and durvalumab to chemotherapy improves progression-free survival and overall survival in patients with metastatic non-small cell lung cancer, phase 3 data suggest.
Researchers have identified factors associated with survival outcomes in NSCLC patients treated with immunotherapy or immunochemotherapy.
The approval was based on data from the phase 3 POSEIDON study.
Lung cancer among never-smokers is the 11th most common cancer among men and the 8th most common among women, a study suggests.
The FDA approval was based on data from the phase 3 EMPOWER-Lung 3 trial.
Durvalumab plus chemoradiotherapy is effective and well tolerated in unresectable, stage III non-small cell lung cancer, real-world data suggest.
Proteinuria was more frequent with regorafenib than with axitinib.
In a first-in-human trial of patients with solid tumors, a MYC inhibitor appeared tolerable and enabled nearly half of evaluable patients to maintain stable disease.
Treating oligoprogression with SBRT improved progression-free survival in patients with lung cancer but not in those with breast cancer.
More than 50 cancer groups have issued an urgent call for more lung cancer screening among high-risk people.
Prophylactic radiotherapy of asymptomatic bone metastases can reduce skeletal-related events and improve survival in patients with solid tumors, a study suggests.
Proton FLASH radiotherapy is feasible, safe, and provides pain relief for cancer patients with bone metastases, according to a first-in-human trial.
Adjuvant atezolizumab can prevent recurrence and death, thereby reducing costs, in patients with early non-small cell lung cancer, a study suggests.
Critical variables for 3 of the highest-volume cancers were not measured under the Oncology Care Model, according to researchers.
COVID-19 vaccination is safe for cancer patients receiving immune checkpoint inhibitors and should not interrupt therapy, according to researchers.